Fentanyl, a synthetic opioid, was first developed by Dr. Paul Janssen in the 1960s. From its inception, it was designed to be fast-acting, highly potent, and more readily synthesized than naturally occurring or semisynthetic opioids such as morphine. Fentanyl and its related ultrapotent synthetic opioid (UPSO) analogues exert their primary analgesic effects through binding to the mu-opioid receptor (MOR). Activation of this receptor is also responsible for severe adverse effects, including respiratory depression, overdose, and death.
Since approximately 2010, fentanyl and related UPSOs have driven a dramatic rise in overdose deaths. This increase can be attributed to several key factors. Many UPSOs can be synthesized using relatively accessible precursor chemicals, facilitating production in clandestine laboratory settings. Their high potency allows for rapid adaptation to changes in precursor availability while maintaining pharmacological activity. Additionally, the extreme potency of these compounds means that very small quantities can produce profound effects, enabling their incorporation into other illicit drugs often without the user’s knowledge thereby significantly increasing overdose risk.
From a pharmacodynamic and pharmacokinetic perspective, the rapid onset, high potency, and hydrophobicity (water-repelling) of fentanyl and related UPSOs contribute to their lethality. The primary treatment for fentanyl overdose is the administration of MOR antagonists such as naloxone (Narcan), which reverses opioid effects. However, naloxone is rapidly metabolized in the liver, resulting in a duration of action that is often shorter than that of fentanyl. This mismatch can lead to renarcotization, in which overdose symptoms recur after initial reversal. As a result, multiple doses of naloxone may be required.
Recent developments in illicit drug use include the increasing prevalence of fentanyl in combination with other substances, such as methamphetamine and xylazine. Co-use with stimulants can mask overdose symptoms and lead to unpredictable physiological effects. The addition of xylazine, a non-opioid sedative, has been associated with a surge in overdose cases and complicates treatment, as it does not respond to naloxone. These trends underscore the evolving challenges in addressing fentanyl-related overdoses.